Piramal Pharma turns profitable as Q2 revenue rises 28%
In short
Piramal Pharma reported a net profit of ₹5.58 crore in Q2 FY27, compared with a loss of ₹99.2 crore a year ago. Revenue rose 28% to ₹2,617 crore, and EBITDA margin improved to 13.3%.
The company also lifted its FY27 revenue growth outlook to 19%–20%. This may reassure investors, but the reporting does not say what risks could affect the forecast.
What the reporting says
Piramal Pharma swung to a net profit of ₹5.58 crore in Q2 FY27 from a loss of ₹99.2 crore a year earlier, as revenue rose 28% to ₹2,617 crore and EBITDA margin expanded to 13.3%. The company also raised its FY27 revenue growth outlook to 19%–20% on first-half momentum and improved profitability. The immediate consequence is a stronger earnings profile and a higher guidance range, while execution risks remain unstated.
Why it matters
Piramal Pharma moved from a ₹99.2 crore loss to a ₹5.58 crore profit in Q2 FY27, supported by 28% revenue growth to ₹2,617 crore and an EBITDA margin of 13.3%. It also raised its FY27 revenue growth outlook to 19%–20%, citing first-half momentum and improved profitability. The report points to stronger operating performance for investors, but does not detail any offsetting risks or segment-level weakness.